XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2021
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Oct. 31, 2018
Apr. 30, 2018
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenues                 $ 199,074 $ 371,120    
Grant funding liability                 5,283,271     $ 4,559,721
Revenue under collaborative research and development arrangements                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenues                 $ 65,895 39,615    
Advaccine | Collaborative Arrangement, Product                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront payment received $ 3,000,000                      
Additional revenue to be achieved 206,000,000                      
Collaboration agreement, payment earned $ 2,000,000                      
Royalty period                 10 years      
Annual maintenance fee                 $ 1,500,000      
Annual maintenance period                 5 years      
Revenues                     $ 5,000,000  
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenues                 $ 0   $ 5,000,000  
ApolloBio | Collaborative Arrangement, Product                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Additional revenue to be achieved                 $ 20,000,000      
Royalty period                 10 years      
Period from effective date for termination                 1 year      
Number of days written notice before termination                 90 days      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received     $ 6,900,000                  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Accounts receivable                 $ 3,800,000      
Collaborative agreement, funding to be received               $ 56,000,000        
Collaborative agreement, period to receive funding for research and development               5 years        
Funding received for research and development                 2,000,000 2,400,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received         $ 9,000,000              
Funding received for research and development                 510,000 2,400,000    
Grant funding liability                 2,700,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received     5,000,000                  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received     $ 1,300,000                  
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Funding received for research and development       $ 5,000,000         0 893,000    
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Funding received for research and development           $ 1,100,000 $ 2,200,000   80,000 0    
Grant funding liability                 304,000      
Department of Defence | Collaborative Arrangement, Product                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Contra-research and development expense                 3,200,000 $ 7,800,000    
Accounts receivable                 0     $ 3,600,000
Deferred grant funding, from affiliate                 2,300,000      
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Funding received for research and development   $ 54,500,000                    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Purchase price, procurement contract   $ 10,700,000                    
Collaborative arrangement , revenue from the procurement contract                 $ 0